Pleural effusion in lung cancer: More questions than answers

Respiration

Volumn 83, Issue 5, 2012, Pages 367-376

  Froudarakis, Marios E ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Cyclooxygenase; Epidermal growth factor receptor; Lung cancer; Matrix metalloproteinase; Non small cell lung carcinoma; Pleural effusion; Target therapy; Tyrosine kinase inhibitors; Vascular endothelial growth factor

Indexed keywords

CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; MATRIX METALLOPROTEINASE; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CARCINOGENESIS; GENOMICS; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS; PLEURA EFFUSION; PRIORITY JOURNAL;

ANGIOGENESIS INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE INHIBITORS; MATRIX METALLOPROTEINASES; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; PLEURAL EFFUSION, MALIGNANT; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE ANALYSIS, DNA; SMALL CELL LUNG CARCINOMA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84861115707     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000338169     Document Type: Article

References (81)

1. Froudarakis ME: Diagnosis and management of pleural effusion in lung cancer; in Bouros D (ed): Pleural Diseases, ed 2. New York, Informa, 2009, pp 427-447.
2. Froudarakis ME, Briasoulis E: Advanced non-small cell lung cancer: on relapse rechallenge the tumor, not the patient. BMC Res Notes 2010; 3: 195.
3. Johnston WW: The malignant pleural effusion. A review of cytopathologic diagnoses of 584 specimens from 472 consecutive patients. Cancer 1985; 56: 905-909. (Pubitemid 15228290)
4. Sahn SA: Malignancy metastatic to the pleura. Clin Chest Med 1998; 19: 351-361. (Pubitemid 28277882)
5. Froudarakis ME: Diagnostic work-up of pleural effusions. Respiration 2008; 75: 4-13.
6. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L: The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007; 2: 706-714. (Pubitemid 47357522)
7. Sugiura S, Ando Y, Minami H, Ando M, Sakai S, Shimokata K: Prognostic value of pleural effusion in patients with non-small cell lung cancer. Clin Cancer Res 1997; 3: 47-50 (Pubitemid 27079443)
8. Shepherd FA, Ginsberg RJ, Haddad R, Feld R, Sagman U, Evans WK, DeBoer G, Maki E: Importance of clinical staging in limited small-cell lung cancer: a valuable system to separate prognostic subgroups. The University of Toronto Lung Oncology Group. J Clin Oncol 1993; 11: 1592-1597. (Pubitemid 23228267)
9. Livingston RB, McCracken JD, Trauth CJ, Chen T: Isolated pleural effusion in small cell lung carcinoma: favorable prognosis. A review of the Southwest Oncology Group experience. Chest 1982; 81: 208-211
10. Perng RP, Chen CY, Chang GC, Hsia TC, Hsu NY, Tsai YH, Tsai CM, Yang CH, Chen YM, Yu CJ, Lee JJ, Hsu HS, Yu CT, Kao EL, Chiu CH: Revisit of 1997 TNM staging system -survival analysis of 1,112 lung cancer patients in Taiwan. Jpn J Clin Oncol 2007; 37: 9-15.
11. Shepherd FA, Crowley J, Van Houtte P, Postmus PE, Carney D, Chansky K, Shaikh Z, Goldstraw P: The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol 2007; 2: 1067-1077 (Pubitemid 350307898)
12. Sriram KB, Relan V, Clarke BE, Duhig EE, Yang IA, Bowman RV, Lee YC, Fong KM: Diagnostic molecular biomarkers for malignant pleural effusions. Future Oncol 2011; 7: 737-752.
13. Ishii S, Xu YH, Stratton RH, Roe BA, Merlino GT, Pastan I: Characterization and sequence of the promoter region of the human epidermal growth factor receptor gene. Proc Natl Acad Sci USA 1985; 82: 4920-4924. (Pubitemid 15249917)
14. Clark AJ, Ishii S, Richert N, Merlino GT, Pastan I: Epidermal growth factor regulates the expression of its own receptor. Proc Natl Acad Sci USA 1985; 82: 8374-8378. (Pubitemid 16101081)
15. Froudarakis ME, Sourvinos G, Fournel P, Bouros D, Vergnon JM, Spandidos DA, Siafakas NM: Microsatellite instability and loss of heterozygosity at chromosomes 9 and 17 in non-small cell lung cancer. Chest 1998; 113: 1091-1094. (Pubitemid 28216459)
16. Scagliotti GV, Selvaggi G, Novello S, Hirsch FR: The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res 2004; 10: 4227s-4232s. (Pubitemid 38812451)
17. Giaccone G: The role of gefitinib in lung cancer treatment. Clin Cancer Res 2004; 10: 4233s-4237s. (Pubitemid 38812452)
18. Shepherd FA, Rosell R: Weighing tumor biology in treatment decisions for patients with non-small cell lung cancer. J Thorac Oncol 2007; 2(suppl 2):S68-S76.
19. Huang SF, Liu HP, Li LH, Ku YC, Fu YN, Tsai HY, Chen YT, Lin YF, Chang WC, Kuo HP, Wu YC, Chen YR, Tsai SF: High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004; 10: 8195-203.
20. Sonobe M, Manabe T, Wada H, Tanaka F: Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma. Br J Cancer 2005; 93: 355-363. (Pubitemid 43080038)
21. Shih JY, Gow CH, Yu CJ, Yang CH, Chang YL, Tsai MF, Hsu YC, Chen KY, Su WP, Yang PC: Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. Int J Cancer 2006; 118: 963-969.
22. Zhang X, Chang A: Somatic mutations of the epidermal growth factor receptor and nonsmall-cell lung cancer. J Med Genet 2007; 44: 166-172. (Pubitemid 46580525)
23. Han HS, Eom DW, Kim JH, Kim KH, Shin HM, An JY, Lee KM, Choe KH, Lee KH, Kim ST, Koo JH, Lee HC, Lee OJ: EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases. Clin Lung Cancer 2011; 12: 380-386.
24. Kalikaki A, Koutsopoulos A, Trypaki M, Souglakos J, Stathopoulos E, Georgoulias V, Mavroudis D, Voutsina A: Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer 2008; 99: 923-929.
25. Kimura H, Fujiwara Y, Sone T, Kunitoh H, Tamura T, Kasahara K, Nishio K: High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients. Cancer Sci 2006; 97: 642-648. (Pubitemid 44056613)
26. Asano H, Toyooka S, Tokumo M, Ichimura K, Aoe K, Ito S, Tsukuda K, Ouchida M, Aoe M, Katayama H, Hiraki A, Sugi K, Kiura K, Date H, Shimizu N: Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. Clin Cancer Res 2006; 12: 43-48. (Pubitemid 43166174)
27. Zhang X, Zhao Y, Wang M, Yap WS, Chang AY: Detection and comparison of epidermal growth factor receptor mutations in cells and fluid of malignant pleural effusion in nonsmall cell lung cancer. Lung Cancer 2008; 60: 175-182. (Pubitemid 351609150)
28. Tsai TH, Su KY, Wu SG, Chang YL, Luo SC, Jan IS, Yu CJ, Yu SL, Shih JY, Yang PC: RNA is favorable for analyzing EGFR mutations in malignant pleural effusion of lung cancer. Eur Respir J 2012; 39: 677-684.
29. Wu SG, Gow CH, Yu CJ, Chang YL, Yang CH, Hsu YC, Shih JY, Lee YC, Yang PC: Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma. Eur Respir J 2008; 32: 924-930.
30. Kimura H, Fujiwara Y, Sone T, Kunitoh H, Tamura T, Kasahara K, Nishio K: EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib. Br J Cancer 2006; 95: 1390-1395. (Pubitemid 44760091)
31. Tanaka T, Nagai Y, Miyazawa H, Koyama N, Matsuoka S, Sutani A, Huqun, Udagawa K, Murayama Y, Nagata M, Shimizu Y, Ikebuchi K, Kanazawa M, Kobayashi K, Hagiwara K: Reliability of the peptide nucleic acidlocked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers. Cancer Sci 2007; 98: 246-252. (Pubitemid 44941878)
32. Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES, Zakowski MF, Kris MG, Ladanyi M, Miller VA: Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006; 12: 839-844. (Pubitemid 43259866)
33. Jian G, Songwen Z, Ling Z, Qinfang D, Jie Z, Liang T, Caicun Z: Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer. J Cancer Res Clin Oncol 2010; 136: 1341-1347.
34. Swiderek J, Morcos S, Donthireddy V, Surapaneni R, Jackson-Thompson V, Schultz L, Kini S, Kvale P: Prospective study to determine the volume of pleural fluid required to diagnose malignancy. Chest 2010; 137: 68-73.
35. Rodriguez-Panadero F: Medical thoracoscopy. Respiration 2008; 76: 363-372.
36. Froudarakis ME: New challenges in medical thoracoscopy. Respiration 2011; 82: 197-200.
37. Froudarakis ME, Noppen M: Medical thoracoscopy: new tricks for an old trade. Respiration 2009; 78: 373-374.
38. Arcila ME, Oxnard GR, Nafa K, Riely GJ, Solomon SB, Zakowski MF, Kris MG, Pao W, Miller VA, Ladanyi M: Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res 2011; 17: 1169-1180.
39. Hung MS, Lin CK, Leu SW, Wu MY, Tsai YH, Yang CT: Epidermal growth factor receptor mutations in cells from non-small cell lung cancer malignant pleural effusions. Chang Gung Med J 2006; 29: 373-379.
40. Soh J, Toyooka S, Aoe K, Asano H, Ichihara S, Katayama H, Hiraki A, Kiura K, Aoe M, Sano Y, Sugi K, Shimizu N, Date H: Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer. Int J Cancer 2006; 119: 2353-2358. (Pubitemid 44546955)
41. Chen P, Wang L, Liu B, Zhang HZ, Liu HC, Zou Z: EGFR-targeted therapies combined with chemotherapy for treating advanced non-small-cell lung cancer: a meta-analysis. Eur J Clin Pharmacol 2011; 67: 235-243.
42. Joerger M, Matter-Walstra K, Fruh M, Kuhnel U, Szucs T, Pestalozzi B, Schwenkglenks M: Addition of cetuximab to first-line chemotherapy in patients with advanced nonsmall-cell lung cancer: a cost-utility analysis. Ann Oncol 2011; 22: 567-574.
43. Shiao TH, Chang YL, Yu CJ, Chang YC, Hsu YC, Chang SH, Shih JY, Yang PC: Epidermal growth factor receptor mutations in small cell lung cancer: a brief report. J Thorac Oncol 2011; 6: 195-198.
44. Pircher A, Hilbe W, Heidegger I, Drevs J, Tichelli A, Medinger M: Biomarkers in tumor angiogenesis and anti-angiogenic therapy. Int J Mol Sci 2011; 12: 7077-7099.
45. Yano S, Matsumori Y, Ikuta K, Ogino H, Doljinsuren T, Sone S: Current status and perspective of angiogenesis and antivascular therapeutic strategy: non-small cell lung cancer. Int J Clin Oncol 2006; 11: 73-81.
46. Cabebe E, Wakelee H: Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr Treat Options Oncol 2007; 8: 15-27.
47. Yano S, Nishioka Y, Goto H, Sone S: Molecular mechanisms of angiogenesis in nonsmall cell lung cancer, and therapeutics targeting related molecules. Cancer Sci 2003; 94: 479-485. (Pubitemid 36849709)
48. Horn L, Sandler AB: Angiogenesis in the treatment of non-small cell lung cancer. Proc Am Thorac Soc 2009; 6: 206-217.
49. Cheng D, Rodriguez RM, Perkett EA, Rogers J, Bienvenu G, Lappalainen U, Light RW: Vascular endothelial growth factor in pleural fluid. Chest 1999; 116: 760-765. (Pubitemid 29428497)
50. Matsuyama W, Hashiguchi T, Mizoguchi A, Iwami F, Kawabata M, Arimura K, Osame M: Serum levels of vascular endothelial growth factor dependent on the stage progression of lung cancer. Chest 2000; 118: 948-951.
51. Zhou WB, Bai M, Jin Y: Diagnostic value of vascular endothelial growth factor and endostatin in malignant pleural effusions. Int J Tuberc Lung Dis 2009; 13: 381-386.
52. Cheng M, Chen Y, Yu X, Tian Z, Wei H: Diagnostic utility of LunX mRNA in peripheral blood and pleural fluid in patients with primary non-small cell lung cancer. BMC Cancer 2008; 8: 156.
53. Hsu IL, Su WC, Yan JJ, Chang JM, Lai WW: Angiogenetic biomarkers in non-small cell lung cancer with malignant pleural effusion: correlations with patient survival and pleural effusion control. Lung Cancer 2009; 65: 371-376.
54. Yano S, Shinohara H, Herbst RS, Kuniyasu H, Bucana CD, Ellis LM, Fidler IJ: Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am J Pathol 2000; 157: 1893-1903.
55. Matsumori Y, Yano S, Goto H, Nakataki E, Wedge SR, Ryan AJ, Sone S: ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a nonsmall cell lung cancer model. Oncol Res 2006; 16: 15-26. (Pubitemid 44195046)
56. Grove CS, Lee YC: Vascular endothelial growth factor: the key mediator in pleural effusion formation. Curr Opin Pulm Med 2002; 8: 294-301. (Pubitemid 34625963)
57. Miserocchi G: Physiology and pathophysiology of pleural fluid turnover. Eur Respir J 1997; 10: 219-225. (Pubitemid 27047206)
58. Jantz MA, Antony VB: Pathophysiology of the pleura. Respiration 2008; 75: 121-133. (Pubitemid 351363863)
59. Pichelmayer O, Gruenberger B, Zielinski C, Raderer M: Bevacizumab is active in malignant effusion. Ann Oncol 2006; 17: 1853.
60. Ishida A, Ishikawa F, Nakamura M, Miyazu YM, Mineshita M, Kurimoto N, Koike J, Nishisaka T, Miyazawa T, Astoul P: Narrow band imaging applied to pleuroscopy for the assessment of vascular patterns of the pleura. Respiration 2009; 78: 432-439.
61. Sessa C, Guibal A, Del Conte G, Ruegg C: Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? Nat Clin Pract Oncol 2008; 5: 378-391. (Pubitemid 351958963)
62. Murphy G, Docherty AJ: The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol 1992; 7: 120-125.
63. Ray JM, Stetler-Stevenson WG: The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur Respir J 1994; 7: 2062-2072. (Pubitemid 24366302)
64. O'Connor CM, FitzGerald MX: Matrix metalloproteases and lung disease. Thorax 1994; 49: 602-609.
65. Eickelberg O, Sommerfeld CO, Wyser C, Tamm M, Reichenberger F, Bardin PG, Soler M, Roth M, Perruchoud AP: MMP and TIMP expression pattern in pleural effusions of different origins. Am J Respir Crit Care Med 1997; 156: 1987-1992. (Pubitemid 28011811)
66. Passlick B, Sienel W, Seen-Hibler R, Wockel W, Thetter O, Mutschler W, Pantel K: Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer. Clin Cancer Res 2000; 6: 3944-3948.
67. Brown PD, Bloxidge RE, Stuart NS, Gatter KC, Carmichael J: Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J Natl Cancer Inst 1993; 85: 574-578. (Pubitemid 23110933)
68. Di Carlo A, Terracciano D, Mariano A, Macchia V: Matrix metalloproteinase-2 and matrix metalloproteinase-9 type IV collagenases in serum of patients with pleural effusions. Int J Oncol 2005; 26: 1363-1368.
69. Hoheisel G, Sack U, Hui DS, Huse K, Chan KS, Chan KK, Hartwig K, Schuster E, Scholz GH, Schauer J: Occurrence of matrix metalloproteinases and tissue inhibitors of metalloproteinases in tuberculous pleuritis. Tuberculosis (Edinb) 2001; 81: 203-209. (Pubitemid 32575228)
70. Di Carlo A, Mariano A, Terracciano D, Mazzarella C, Galzerano S, Cicalese M, Cecere C, Macchia V: Gelatinolytic activities (matrix metalloproteinase-2 and -9) and soluble extracellular domain of Her-2/neu in pleural effusions. Oncol Rep 2007; 18: 425-431.
71. Park KJ, Hwang SC, Sheen SS, Oh YJ, Han JH, Lee KB: Expression of matrix metalloproteinase-9 in pleural effusions of tuberculosis and lung cancer. Respiration 2005; 72: 166-175. (Pubitemid 40591530)
72. Johnatty RN, Taub DD, Reeder SP, Turcovski-Corrales SM, Cottam DW, Stephenson TJ, Rees RC: Cytokine and chemokine regulation of proMMP-9 and TIMP-1 production by human peripheral blood lymphocytes. J Immunol 1997; 158: 2327-2333. (Pubitemid 127470018)
73. Goetzl EJ, Banda MJ, Leppert D: Matrix metalloproteinases in immunity. J Immunol 1996; 156: 1-4. (Pubitemid 26006939)
74. Shepherd FA, Giaccone G, Seymour L, Debruyne C, Bezjak A, Hirsh V, Smylie M, Rubin S, Martins H, Lamont A, Krzakowski M, Sadura A, Zee B: Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20: 4434-4439. (Pubitemid 35334754)
75. Bissett D, O'Byrne KJ, von Pawel J, Gatzemeier U, Price A, Nicolson M, Mercier R, Mazabel E, Penning C, Zhang MH, Collier MA, Shepherd FA: Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J Clin Oncol 2005; 23: 842-849. (Pubitemid 46224184)
76. Douillard JY, Peschel C, Shepherd F, Paz-Ares L, Arnold A, Davis M, Tonato M, Smylie M, Tu D, Voi M, Humphrey J, Ottaway J, Young K, Vreckem AV, Seymour L: Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer. Lung Cancer 2004; 46: 361-368. (Pubitemid 39487312)
77. Macaulay VM, O'Byrne KJ, Saunders MP, Braybrooke JP, Long L, Gleeson F, Mason CS, Harris AL, Brown P, Talbot DC: Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin Cancer Res 1999; 5: 513-520. (Pubitemid 29131959)
78. Brown JR, DuBois RN: Cyclooxygenase as a target in lung cancer. Clin Cancer Res 2004; 10: 4266s-4269s. (Pubitemid 38812460)
79. Gridelli C, Gallo C, Ceribelli A, Gebbia V, Gamucci T, Ciardiello F, Carozza F, Favaretto A, Daniele B, Galetta D, Barbera S, Rosetti F, Rossi A, Maione P, Cognetti F, Testa A, Di Maio M, Morabito A, Perrone F: Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. Lancet Oncol 2007; 8: 500-512. (Pubitemid 46805905)
80. Agarwala A, Fisher W, Bruetman D, Mc-Clean J, Taber D, Titzer M, Juliar B, Yu M, Breen T, Einhorn LH, Hanna N: Gefitinib plus celecoxib in chemotherapy-naive patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group. J Thorac Oncol 2008; 3: 374-379. (Pubitemid 351489477)
81. Pace E, Siena L, Ferraro M, Profita M, Mondello P, Chiappara G, Montalbano AM, Giarratano A, Bonsignore G, Gjomarkaj M: Role of prostaglandin E2 in the invasiveness, growth and protection of cancer cells in malignant pleuritis. Eur J Cancer 2006; 42: 2382-2389. (Pubitemid 44307619)